Dyspnea |
|
Cough |
|
Pneumothorax |
Intrapleural drain, needle aspiration, pleural rubbing, chemical pleurodesis, total pleural covering techniques, and bullectomy
13,21
–23
|
Hemothorax |
Pleural drainage and vascular embolization
25
Celiprolol to reduce vascular stress in vEDS
26
Lifestyle changes to minimize risk of trauma, individualized emergency plans, centralized management, and blood pressure control Tranexamic acid (for recurrent hemoptysis)
44
Annual monitoring of the vascular tree utilizing ultrasound, CT-arteriography and nuclear magnetic resonance
27
|
Tissue Fragility and Risk |
Avoid use of fluoroquinolones, bronchoscopy, arterial blood gases, and careful discussion regarding surgery
|
Chest Wall Abnormalities |
|
Respiratory Muscle Weakness |
|
Diaphragmatic Rupture
|
Surgical correction of diaphragmatic rupture/reduction of herniation of abdominal contents
28,29
Aggressive management: oxygenation, ventilation, and fluid resuscitation
30
|
Lung Herniation |
|
Asthma |
Review of symptoms, risk factors and triggers (i.e. smoking, allergens, etc.)
Evaluation of comorbidities (i.e. obesity, GERD, OSA, MCAS, etc.)
Physical activity
Action Plan
|
Mast Cell Activation Syndrome (MCAS) |
Identify potential symptom triggers (i.e. dietary, chemicals, allergens)
32
Identify other triggers: alcohol, heat, radiocontrast dye, physical stimuli, exercise, and emotional stress
Desensitization therapy and pharmacological therapy (i.e., H1 and H2 antihistamines, sodium cromoglycate, ketotifen, omalizumab and leukotriene receptor blockers)
|
Dysphonia |
|
Tracheal Stenosis |
Surgical correction
33
Mechanical dilation
34
|
Obstructive Sleep Apnea |
|
Hematoma Cavitary Lesions Fibrous Nodules |
|